Related Experiment Video
Updated: Jun 2, 2026

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
Increased serum nitric oxide metabolites in dysglycaemia
Asghar Ghasemi1, Saleh Zahediasl, Iraj Azimzadeh
1Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background:
Nitric oxide plays an important role in hyperglycaemia-induced endothelial dysfunction.
Aim:
To investigate the relationship between serum nitric oxide metabolite (NO(x)) levels and fasting glucose in a population-based study.
Subjects And Method:
Serum concentration of NO(x) was measured by the Griess method in 3,505 participants, aged 20-94 years, selected from a population-based study.
Results:
In men with impaired fasting glucose, each mmol/L increase in fasting serum glucose increased probability of serum NO(x) levels higher than median (> 25 μM) by 3.05-times (OR = 3.05 [95% CI, 1.15-8.07], p = 0.025) in non-adjusted and 3.76-times (OR = 3.76 [95% CI, 1.34-10.53, p = 0.012) in multivariable-adjusted analyses, while no significant associations were found in women. A direct association between fasting glucose categories and NO(x) values was found in men after multivariable adjustment (p = 0.006). Multivariable-adjusted serum NO(x) was significantly (p = 0.008) higher in diabetic men [34.1 (29.5-39.6) μmol/L] compared to non-diabetic ones [29.7 (26.5-33.2) μmol/L].
Conclusion:
The findings show increased serum NO(x) levels in men, but not women, with impaired fasting glucose and diabetes in a population-based study.
More Related Videos
08:25Measuring Nitrite and Nitrate, Metabolites in the Nitric Oxide Pathway, in Biological Materials using the Chemiluminescence Method
Published on: December 25, 2016
08:23Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Related Concept Videos
Nitric Oxide Signaling Pathway
Diabetic Neuropathy
Hyperglycemia
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology